Filing Flows › Coherus Oncology (CHRS) › How it makes money
How Coherus Oncology (CHRS) makes money
Coherus Oncology (CHRS) made $14.3M of revenue in the second quarter 2026 (Q2 2026), +40% from a year earlier. Toripalimab brought in $13.6M (95%); Other revenue brought in $694K (5%).
Drawing the Sankey…
Revenue by segment, Q2 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Toripalimab | $13.6M | 95.1% | +15% | +37% |
| Other revenue | $694K | 4.9% | +37% | +135% |
Where each dollar of revenue goes
| Line | Q2 2026 | % of revenue |
|---|---|---|
| Revenue | $14.3M | 100.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q2 2026 | $14.3M | +40% |
| Q1 2026 | $12.3M | +62% |
| Q4 2025 | $12.7M | +65% |
| Q3 2025 | $11.6M | +91% |
| Q2 2025 | $10.3M | -0.4% |
| Q1 2025 | $7.6M | +229% |
| Q4 2024 | $54.1M | -41% |
From Coherus Oncology's 10-Q filed Aug 5, 2026 (on EDGAR).
Questions
How does Coherus Oncology make money?
Coherus Oncology (CHRS) made $14.3M of revenue in the second quarter 2026 (Q2 2026), +40% from a year earlier. Toripalimab brought in $13.6M (95%); Other revenue brought in $694K (5%).
What is Coherus Oncology's biggest business?
Toripalimab: $13.6M in the second quarter 2026, 95% of revenue, +37% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.